The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms
暂无分享,去创建一个
R. Greil | T. Melchardt | A. Egle | T. Magnes | Dominik Kiem | S. Wagner
[1] R. Teruel-Montoya,et al. Emerging Role of Neutrophils in the Thrombosis of Chronic Myeloproliferative Neoplasms , 2021, International journal of molecular sciences.
[2] T. Barbui,et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. , 2021, The Lancet. Haematology.
[3] S. Verstovsek,et al. Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden. , 2020, Blood advances.
[4] A. Tefferi,et al. Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management , 2020, American journal of hematology.
[5] G. Li Volti,et al. The Role of Inflammation and Inflammasome in Myeloproliferative Disease , 2020, Journal of clinical medicine.
[6] G. Hobbs,et al. Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature , 2020, Cancers.
[7] N. Komatsu,et al. Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin , 2020, Cancer science.
[8] R. Levine,et al. Secondary leukemia to myeloproliferative neoplasms. , 2020, Blood.
[9] Yini Wang,et al. Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis , 2020, Haematologica.
[10] M. Mohty,et al. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. , 2020, The New England journal of medicine.
[11] H. Kantarjian,et al. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring , 2020, American journal of hematology.
[12] M. Arbushites,et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label, phase 2 trial. , 2020, Blood.
[13] S. Verstovsek,et al. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure , 2020, American journal of hematology.
[14] R. Greil,et al. Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera. , 2020, Drugs of today.
[15] K. Krejcy,et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. , 2020, The Lancet. Haematology.
[16] P. Nigrovic,et al. Megakaryocyte emperipolesis: a new frontier in cell-in-cell interaction , 2019, Platelets.
[17] L. Bullinger,et al. Single-cell analysis based dissection of clonality in myelofibrosis , 2019, Nature Communications.
[18] Michael Schieber,et al. Myelofibrosis in 2019: moving beyond JAK2 inhibition , 2019, Blood Cancer Journal.
[19] F. Heidel,et al. Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation , 2019, Cells.
[20] R. Murphy,et al. Review of primary and secondary erythromelalgia , 2019, Clinical and experimental dermatology.
[21] B. Engelmann,et al. Platelet–Neutrophil Crosstalk in Atherothrombosis , 2019, Thrombosis and Haemostasis.
[22] P. Heller,et al. Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms , 2019, Front. Immunol..
[23] T. Barbui,et al. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. , 2019, Blood advances.
[24] C. James,et al. High circulating levels of MPO-DNA are associated with thrombosis in patients with MPN , 2019, Leukemia.
[25] U. Gianelli,et al. Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options , 2019, International journal of molecular sciences.
[26] S. D. De Meyer,et al. Neutrophil Extracellular Traps in Arterial and Venous Thrombosis , 2019, Seminars in Thrombosis and Hemostasis.
[27] S. Verstovsek,et al. Updates in the management of polycythemia vera and essential thrombocythemia , 2019, Therapeutic advances in hematology.
[28] A. Weyrich,et al. Megakaryocyte emperipolesis mediates membrane transfer from intracytoplasmic neutrophils to platelets , 2018, bioRxiv.
[29] K. Mills,et al. The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms , 2018, Journal of Translational Medicine.
[30] T. Barbui,et al. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk‐stratification and management , 2018, American journal of hematology.
[31] A. Tall,et al. Macrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in Jak2V617F Mice , 2018, Circulation research.
[32] A. Tefferi. Primary myelofibrosis: 2019 update on diagnosis, risk‐stratification and management , 2018, American journal of hematology.
[33] John M. Grosel,et al. Acute portal vein thrombosis in a 59-year-old male with JAK2 V617F mutation☆ , 2018, Radiology case reports.
[34] B. Bauvois,et al. Revisiting Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Cancer: Saint or Sinner? , 2018, Cancers.
[35] H. Amthauer,et al. JAK2-V617F promotes venous thrombosis through &bgr;1/&bgr;2 integrin activation , 2018, The Journal of clinical investigation.
[36] S. Verstovsek,et al. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial , 2018, JAMA oncology.
[37] S. Mccarroll,et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms , 2018, Science Translational Medicine.
[38] T. Barbui,et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion , 2018, Blood Cancer Journal.
[39] A. Green,et al. Myeloproliferative neoplasms: from origins to outcomes. , 2017, Blood.
[40] F. Lussana,et al. Inflammation and myeloproliferative neoplasms. , 2017, Journal of autoimmunity.
[41] V. Papayannopoulos. Neutrophil extracellular traps in immunity and disease , 2017, Nature Reviews Immunology.
[42] R. Mesa,et al. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] R. Gale,et al. Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease. , 2017, Leukemia research.
[44] S. Verstovsek,et al. JAK2 inhibitors for myeloproliferative neoplasms: what is next? , 2017, Blood.
[45] Z. Shun,et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. , 2017, The Lancet. Haematology.
[46] J. Chi,et al. JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics. , 2017, Blood advances.
[47] A. Mead,et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. , 2017, The Lancet. Haematology.
[48] A. Mead,et al. Myeloproliferative neoplasm stem cells. , 2017, Blood.
[49] P. Kubes,et al. An emerging role for neutrophil extracellular traps in noninfectious disease , 2017, Nature Medicine.
[50] B. Schraven,et al. JAK2-V617F activates β1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1 , 2017, Leukemia.
[51] M. Schattner,et al. Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms , 2016, Scientific Reports.
[52] P. Guglielmelli,et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. , 2016, Blood advances.
[53] G. Martinelli,et al. Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study , 2016, Oncotarget.
[54] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[55] A. Tefferi,et al. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors , 2015, Blood Cancer Journal.
[56] F. Fend,et al. Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications , 2015, Modern Pathology.
[57] H. Hasselbalch,et al. MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives , 2015, Mediators of inflammation.
[58] Daniel B. Aruch,et al. Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells. , 2015, Blood.
[59] K. McCoy,et al. IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. , 2015, The Journal of clinical investigation.
[60] A. Tefferi,et al. Myeloproliferative Neoplasms: A Contemporary Review. , 2015, JAMA oncology.
[61] Paola Guglielmelli,et al. Effect of mutation order on myeloproliferative neoplasms. , 2015, The New England journal of medicine.
[62] M. Griesshammer,et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. , 2015, The New England journal of medicine.
[63] Jonathan J. Chen,et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. , 2015, Cancer discovery.
[64] K. Kaushansky,et al. The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm. , 2014, Blood.
[65] S. Akira,et al. JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2. , 2014, Blood.
[66] S. Orkin,et al. Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F , 2014, The Journal of experimental medicine.
[67] D. Kent,et al. Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms. , 2014, Experimental hematology.
[68] M. Jensen,et al. Circulating YKL‐40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state , 2014, European journal of haematology.
[69] E. Ejerblad,et al. Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. , 2014, Leukemia research.
[70] D. Lai,et al. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms , 2014, Nature.
[71] M. Cazzola,et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. , 2014, Blood.
[72] H. Hasselbalch. A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis? , 2014, Leukemia research.
[73] A Caflisch,et al. Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348) , 2014, Leukemia.
[74] F. Passamonti,et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons , 2014, Leukemia.
[75] R. Levine,et al. Genetics of Myeloproliferative Neoplasms , 2014, Cancer journal.
[76] J. D. Fitzpatrick,et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.
[77] T. Barbui,et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. , 2013, Blood.
[78] Nicole C. C. Them,et al. Genetic Basis of MPN: Beyond JAK2-V617F , 2013, Current Hematologic Malignancy Reports.
[79] P. Petrides,et al. Aquagenic pruritus in polycythemia vera: Characteristics and influence on quality of life in 441 patients , 2013, American journal of hematology.
[80] T. Barbui,et al. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis , 2013, Leukemia.
[81] H. Pahl,et al. Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms , 2013, Haematologica.
[82] M. Cazzola,et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study , 2013, Leukemia.
[83] R. Kralovics,et al. Molecular basis and clonal evolution of myeloproliferative neoplasms , 2013, Clinical chemistry and laboratory medicine.
[84] R. Kralovics,et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. , 2013, Blood.
[85] H. Hasselbalch. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? , 2013, Leukemia research.
[86] T. Barbui,et al. Cardiovascular events and intensity of treatment in polycythemia vera. , 2013, The New England journal of medicine.
[87] V. Jooste,et al. Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population‐based study of 327 patients , 2013, British journal of haematology.
[88] P. Campbell,et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. , 2012, Blood.
[89] B. Ebert,et al. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. , 2012, Blood.
[90] G. Finazzi. How to manage essential thrombocythemia , 2012, Leukemia.
[91] H. Hasselbalch,et al. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? , 2012, Blood.
[92] Jason Gotlib,et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.
[93] T. Barbui,et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.
[94] Angela G. Fleischman,et al. TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. , 2011, Blood.
[95] T. Barbui,et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. , 2011, Blood.
[96] J. Mulloy,et al. The Thrombopoietin/MPL pathway in hematopoiesis and leukemogenesis , 2011, Journal of cellular biochemistry.
[97] Z. Estrov,et al. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. , 2011, Cancer research.
[98] D. Kent,et al. Mouse models of myeloproliferative neoplasms: JAK of all grades , 2011, Disease Models & Mechanisms.
[99] A. Tefferi,et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[100] M. Boissinot,et al. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F , 2011, Oncogene.
[101] T. Barbui,et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3 , 2011, Haematologica.
[102] A. Allegra,et al. Increased serum levels of neutrophil gelatinase-associated lipocalin in patients with essential thrombocythemia and polycythemia vera , 2011, Leukemia & lymphoma.
[103] B. Bellosillo,et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. , 2010, Blood.
[104] A. Martínez-Trillos,et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients , 2010, Annals of Hematology.
[105] H. Pahl,et al. AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2. , 2009, Blood.
[106] M. Konopleva,et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[107] S. Adams,et al. Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a , 2009, Journal of Translational Medicine.
[108] S. Chevret,et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. , 2008, Blood.
[109] N. Villamor,et al. Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis , 2008, Annals of Hematology.
[110] M. Møller,et al. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis – impact on disease phenotype , 2007, European journal of haematology.
[111] M. Stratton,et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.
[112] G. Tiscia,et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis , 2007, Journal of thrombosis and haemostasis : JTH.
[113] M. Cazzola,et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. , 2006, Blood.
[114] M. Boissinot,et al. Erythropoietin-independent erythroid colony formation by bone marrow progenitors exposed to interleukin-11 and interleukin-8. , 2005, Experimental hematology.
[115] T. Barbui,et al. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. , 2005, Seminars in hematology.
[116] J. D. van der Walt,et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. , 2005, The New England journal of medicine.
[117] T. Barbui,et al. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. , 2005, Experimental hematology.
[118] Mario Cazzola,et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.
[119] Stefan N. Constantinescu,et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.
[120] T. Maiwald,et al. Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF‐E2 , 2005, British journal of haematology.
[121] Sandra A. Moore,et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.
[122] P. Campbell,et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.
[123] M. Le Bousse-Kerdilès,et al. IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis. , 2005, Blood.
[124] A. Migliaccio,et al. Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice. , 2004, Blood.
[125] R. Landolfi,et al. Efficacy and safety of low-dose aspirin in polycythemia vera , 2004 .
[126] E. Lippert,et al. Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera. , 2002, Cytokine.
[127] C. Burgaleta,et al. Increased CD11/CD18 Expression and Altered Metabolic Activity on Polymorphonuclear Leukocytes from Patients with Polycythemia vera and Essential Thrombocythemia , 2002, Acta Haematologica.
[128] F. Wendling,et al. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. , 2000, Blood.
[129] R. Willemze,et al. Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radioprotective capacity and long-term myelolymphoid repopulating ability. , 1995, Blood.
[130] F. Ambrogi,et al. Neutrophil functions in essential thrombocythemia. , 1993, Hematologic pathology.
[131] D. Buss,et al. The frequency and significance of megakaryocytic emperipolesis in myeloproliferative and reactive states , 1992, Annals of Hematology.
[132] S. Schwartz. Myeloproliferative Disorders , 1975, Annals of surgery.
[133] S. Verstovsek,et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. , 2018, The Lancet. Haematology.
[134] M. Griesshammer,et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. , 2017, The Lancet. Oncology.
[135] T. Barbui,et al. Preview : Published ahead of advance online publication Myeloproliferative neoplasms and inflammation : Whether to target the malignant clone or the inflammatory process or both , 2016 .
[136] C. Creighton,et al. Bone Marrow Stroma – Secreted Cytokines Protect JAK2 V617F -Mutated Cells from the Effects of a JAK2 Inhibitor , 2011 .
[137] W. Vainchenker,et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. , 2007, Blood.
[138] N. Villamor,et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. , 2006, Haematologica.